Latest News
Portfolio updates, investments, exits and press releases from Kurma Partners.
January 2026
Alveus Therapeutics launches with $160 Million Series A Financing to Advance Next-Generation Therapies for Obesity and Metabolic Diseases
Advancing next-generation therapies for obesity and metabolic diseases with a landmark funding round.
Read more
January 2026
PathoQuest, a Kurma Partners portfolio company, announces a definitive agreement to be acquired by Charles River Laboratories
A definitive agreement marking a successful exit for this Kurma Partners portfolio company in the diagnostics space.
Read more
October 2025
Kurma Partners announces the sale of ImCheck to Ipsen for up to €1 billion
A landmark transaction confirming the value creation of Kurma's investment strategy in immuno-oncology.
Read more
July 2025
Kurma Growth Opportunities Fund co-leads EUR 84M financing of NUCLIDIUM
Scaling a copper-based radiopharmaceutical platform to address high unmet medical needs in oncology.
Read more
December 2025
Laigo Bio raises EUR 11.5 million in seed financing
A new Kurma Biofund IV portfolio company enters the arena with seed funding to develop innovative biotechnology solutions.
Read more
2024
Adcytherix launched with Kurma Partners as founding investor
Kurma Partners participates as founding investor in the launch of Adcytherix, a next-generation ADC company.
Read more
2024
Kurma Biofund IV reaches first closing at 158M€
Kurma Partners' fourth flagship biotech fund achieves a strong first closing, reinforcing its position as a leading European healthcare investor.
Read more2024
Kurma Growth Opportunities reaches first closing at 167M€
The growth fund dedicated to late-stage and cross-over investments in healthcare achieves its initial target.
Read more
2024
Germitec secures new round of financing for UV-C medical device disinfection
Germitec, pioneer of automated high-level disinfection for ultrasound probes, raises additional capital to expand commercial reach.
Read more
March 2025
Flamingo Therapeutics raises €42M Series B for next-generation RNA delivery
Flamingo Therapeutics secures Series B financing to advance its proprietary lipid nanoparticle platform for RNA therapeutics.
Read more
May 2025
Corlieve Therapeutics advances gene therapy candidate into clinical trials for focal epilepsy
A milestone for this Kurma-backed gene therapy company targeting neurological disorders with precision medicine approaches.
Read more
June 2025
Smart Catch receives CE marking for AI-powered cervical cancer screening device
Smart Catch's diagnostic device achieves European regulatory approval, enabling broader deployment across healthcare systems.
Read more
February 2025
Pharvaris reports positive Phase 3 results for oral bradykinin B2 receptor antagonist
Pharvaris announces pivotal data supporting its lead candidate for hereditary angioedema, a key growth portfolio holding.
Read more
September 2024
Rycarma raises €18M to develop allogeneic CAR-T cell therapies
Kurma Biofund IV backs Rycarma's innovative off-the-shelf cell therapy approach for hematological cancers.
Read more
November 2023
Kiro raises €23M Series B for robotic chemotherapy preparation
Kiro, a Kurma Diagnostics portfolio company, secures growth financing to scale its automated oncology pharmacy platform.
Read more2023
Kurma Partners becomes a subsidiary of the Eurazeo Group
Kurma Partners joins Eurazeo, one of the leading global investment companies, strengthening its platform for healthcare venture capital.
Read more
June 2023
Amolyt Pharma acquired by AstraZeneca for up to $1.05 billion
Another landmark exit for Kurma's biotech portfolio as AstraZeneca acquires Amolyt Pharma for its endocrinology pipeline.
Read more
March 2023
Step Pharma raises €37M Series B for purine synthesis inhibitors in oncology
Step Pharma secures significant Series B round to advance its first-in-class oncology and autoimmunity pipeline.
Read more